Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 11Head and Neck Neoplasms 5Breast Neoplasms 3Adenocarcinoma of Lung 3Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Gliosarcoma 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Brain Neoplasms 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Untreated Childhood Anaplastic Astrocytoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Salivary Gland Neoplasms 1Recurrence 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Lymphoid Interstitial Pneumonia 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1

Interventions

Radiotherapy 11Cisplatin 10Paclitaxel 9pembrolizumab 7Fluorouracil 7Oxaliplatin 6Irinotecan 6tislelizumab 5Cetuximab 5Docetaxel 4Radiation 3Nivolumab 3Leucovorin 3Carboplatin 3Capecitabine 3Neoadjuvant Therapy 2Immunohistochemistry 2Biopsy 210-propargyl-10-deazaaminopterin 2tremelimumab 1sitravatinib 1sintilimab 1regorafenib 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1oblimersen 1durvalumab 1cixutumumab 1adavosertib 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Esophageal Squamous Cell Carcinoma × Gefitinib × Clear all
NCT00268346 2016-01-05

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

Case Comprehensive Cancer Center

Phase 2 Completed
58 enrolled 6 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡